You are currently viewing a new version of our website. To view the old version click .

Vaccines, Volume 10, Issue 2

February 2022 - 207 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Cover Story: Shigella sonnei and flexneri remain among the top bacterial causes of dysentery and severe diarrhea in children. Several vaccine developers are in advanced clinical studies with highly promising multivalent formulations; a safe and efficacious Shigella vaccine would represent a great scientific achievement. Nonetheless, such a vaccine would arrive in the context of increasingly crowded and costly childhood immunization programs, among a myriad of other new and improved vaccines currently or soon on the market. There is thus no guarantee that a Shigella vaccine would become an adoption priority by those low- and middle-income countries that could benefit the most. We discuss some of the major determinants of the introduction of Shigella vaccines and the importance of developing a succinct, compelling public health value proposition. View this paper

Articles (207)

  • Review
  • Open Access
63 Citations
16,887 Views
32 Pages

Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective

  • Abid A. Haseeb,
  • Omar Solyman,
  • Mokhtar M. Abushanab,
  • Ahmed S. Abo Obaia and
  • Abdelrahman M. Elhusseiny

21 February 2022

Vaccination efforts as a mitigation strategy in the corona virus disease 2019 (COVID-19) pandemic are fully underway. A vital component of understanding the optimal clinical use of these vaccines is a thorough investigation of adverse events followin...

  • Article
  • Open Access
12 Citations
2,917 Views
8 Pages

SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot

  • Lutz Achtnichts,
  • Arkady Ovchinnikov,
  • Barbara Jakopp,
  • Michael Oberle,
  • Krassen Nedeltchev,
  • Christoph Andreas Fux,
  • Johann Sellner and
  • Oliver Findling

21 February 2022

Evidence suggests limited development of protective IgG responses to mRNA-based vaccines in sphingosine-1-phosphate receptor (S1PR)-modulator treated individuals with multiple sclerosis (MS). We studied the extent of the humoral immune response after...

  • Article
  • Open Access
20 Citations
4,225 Views
15 Pages

Evaluation of the Safety, Tolerability and Immunogenicity of ShigETEC, an Oral Live Attenuated Shigella-ETEC Vaccine in Placebo-Controlled Randomized Phase 1 Trial

  • Petra Girardi,
  • Shushan Harutyunyan,
  • Irene Neuhauser,
  • Katharina Glaninger,
  • Orsolya Korda,
  • Gábor Nagy,
  • Eszter Nagy,
  • Valéria Szijártó,
  • Denes Pall and
  • Krisztina Szarka
  • + 3 authors

21 February 2022

Background: Shigella spp. and enterotoxigenic Escherichia coli (ETEC) cause high morbidity and mortality worldwide, yet no licensed vaccines are available to prevent corresponding infections. A live attenuated non-invasive Shigella vaccine strain lac...

  • Article
  • Open Access
8 Citations
2,603 Views
12 Pages

The Humoral Immune Response of the ChAdOx1 nCoV-19 Vaccine in Maintenance Dialysis Patients without Prior COVID-19 Infection

  • Chung-Yi Cheng,
  • Te-Chao Fang,
  • Hung-Wei Liao,
  • Tso-Hsiao Chen,
  • Jer-Hwa Chang,
  • Yen-Chung Lin,
  • Chih-Chin Kao,
  • Ming-Che Liu,
  • Hui-Wen Chang and
  • Ching-Sheng Hung
  • + 3 authors

21 February 2022

Background: Chronic kidney disease (CKD) patients tend to have a reduced immune response to infection and vaccination. The efficacy of current available COVID-19 vaccines in CKD patients has not been widely evaluated. Methods: In the present study, t...

  • Review
  • Open Access
5 Citations
4,313 Views
24 Pages

Four Faces of Cell-Surface HLA Class-I: Their Antigenic and Immunogenic Divergence Generating Novel Targets for Vaccines

  • Mepur H. Ravindranath,
  • Narendranath M. Ravindranath,
  • Senthamil R. Selvan,
  • Edward J. Filippone,
  • Carly J. Amato-Menker and
  • Fatiha El Hilali

21 February 2022

Leukocyte cell-surface HLA-I molecules, involved in antigen presentation of peptides to CD8+ T-cells, consist of a heavy chain (HC) non-covalently linked to β2-microglobulin (β2m) (Face-1). The HC amino acid composition varies across all si...

  • Article
  • Open Access
9 Citations
3,136 Views
12 Pages

Association of SARS-CoV-2 Vaccinations with SARS-CoV-2 Infections, ICU Admissions and Deaths in Greece

  • Foteini Malli,
  • Ioannis C. Lampropoulos,
  • Dimitrios Papagiannis,
  • Ioanna V. Papathanasiou,
  • Zoe Daniil and
  • Konstantinos I. Gourgoulianis

21 February 2022

The available coronavirus disease 2019 (COVID-19) vaccines have shown their effectiveness in clinical trials. We aimed to assess the real-world effects of SARS-CoV-2 vaccinations in Greece. We combined national data on vaccinations, SARS-CoV-2 cases,...

  • Communication
  • Open Access
5 Citations
2,407 Views
9 Pages

20 February 2022

To control the coronavirus disease 2019 (COVID-19) pandemic, the Japanese government is promoting vaccination, which many people are willing to accept; however, some are reluctant to receive vaccinations. The purpose of this study was to analyze the...

  • Article
  • Open Access
3 Citations
4,180 Views
17 Pages

Protection of Cattle against Epizootic Bovine Abortion (EBA) Using a Live Pajaroellobacter abortibovis Vaccine

  • Myra T. Blanchard,
  • Mike B. Teglas,
  • Mark L. Anderson,
  • Peter F. Moore,
  • Bret R. McNabb,
  • Kassidy M. Collins,
  • Bret V. Yeargan and
  • Jeffrey L. Stott

19 February 2022

Epizootic bovine abortion (EBA) is an arthropod-borne bacterial disease that causes significant economic loss for cattle producers in the western United States. The etiologic agent, Pajaroellobacter abortibovis, is an intracellular pathogen that has...

  • Article
  • Open Access
6 Citations
3,231 Views
10 Pages

19 February 2022

Systemic vaccination with the BNT162b2 mRNA vaccine stimulates the humoral response. Our study aimed to compare the intensity of the humoral immune response, measured by SARS-CoV-2 IgG, SARS-CoV-2 IgM, and S-RBD-neutralizing IgG antibody levels after...

  • Article
  • Open Access
13 Citations
4,065 Views
11 Pages

Humoral and Cellular Responses to COVID-19 Vaccines in SARS-CoV-2 Infection-Naïve and -Recovered Korean Individuals

  • Ji-Young Hwang,
  • Yunhwa Kim,
  • Kyung-Min Lee,
  • Eun-Jeong Jang,
  • Chang-Hoon Woo,
  • Chang-Ui Hong,
  • Seok-Tae Choi,
  • Sivilay Xayaheuang,
  • Jong-Geol Jang and
  • June-Hong Ahn
  • + 1 author

18 February 2022

In the face of a global COVID-19 vaccine shortage, an efficient vaccination strategy is required. Therefore, the immunogenicity of single or double COVID-19 vaccination doses (ChAdOX1, BNT162b2, or mRNA-1273) of SARS-CoV-2-recovered individuals was c...

of 21